Zealand Pharma and Boehringer Ingelheim Team Up to Transform Liver Fibrosis Treatment for F2 and F3 Patients

Friday, 7 June 2024, 05:48

Zealand Pharma and Boehringer Ingelheim have made a significant breakthrough in treating liver fibrosis with their drug, survodutide. The latest clinical trials demonstrate a remarkable 64.5% improvement in patients with F2 and F3 fibrosis, without exacerbating MASH. This development offers hope for those suffering from advanced liver conditions, marking a positive step towards more effective treatments in the near future.
https://store.livarava.com/bd8b510d-24ad-11ef-a412-9d5fa15a64d8.jpg
Zealand Pharma and Boehringer Ingelheim Team Up to Transform Liver Fibrosis Treatment for F2 and F3 Patients

Breakthrough Improvement in Liver Fibrosis

Zealand Pharma announces collaboration with Boehringer Ingelheim

  • Survodutide shows breakthrough improvement in liver fibrosis
  • No worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

Zealand Pharma reveals the successful outcome of the latest clinical trials, where survodutide developed in partnership with Boehringer Ingelheim demonstrates remarkable efficacy in treating liver fibrosis, particularly in patients with advanced stages (F2 and F3) without worsening of MASH.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe